Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 10,000 Shares

Pharvaris N.V. (NASDAQ:PHVS) Director Robert Glassman sold 10,000 shares of the business’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $29.82, for a total value of $298,200.00. Following the completion of the transaction, the director directly owned 10,500 shares in the company, valued at approximately $313,110. This represents a 48.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Pharvaris Stock Performance

Pharvaris stock traded up $0.14 on Tuesday, reaching $28.95. The company’s stock had a trading volume of 301,435 shares, compared to its average volume of 226,184. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -9.10 and a beta of -2.34. The business’s fifty day moving average price is $28.20 and its 200 day moving average price is $26.63. Pharvaris N.V. has a twelve month low of $15.46 and a twelve month high of $33.33.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. As a group, equities analysts forecast that Pharvaris N.V. will post -3.35 earnings per share for the current year.

Hedge Funds Weigh In On Pharvaris

Several institutional investors have recently modified their holdings of PHVS. Stempoint Capital LP increased its stake in shares of Pharvaris by 48.4% in the 1st quarter. Stempoint Capital LP now owns 86,637 shares of the company’s stock valued at $2,447,000 after acquiring an additional 28,248 shares during the last quarter. ADAR1 Capital Management LLC raised its position in shares of Pharvaris by 23.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 105,528 shares of the company’s stock valued at $2,981,000 after acquiring an additional 20,000 shares during the period. Amundi boosted its stake in Pharvaris by 12.0% during the 1st quarter. Amundi now owns 30,952 shares of the company’s stock worth $874,000 after acquiring an additional 3,312 shares during the last quarter. Rock Springs Capital Management LP boosted its stake in Pharvaris by 3.6% during the 1st quarter. Rock Springs Capital Management LP now owns 645,533 shares of the company’s stock worth $18,236,000 after acquiring an additional 22,131 shares during the last quarter. Finally, SummitTX Capital L.P. boosted its stake in Pharvaris by 27.7% during the 1st quarter. SummitTX Capital L.P. now owns 29,184 shares of the company’s stock worth $824,000 after acquiring an additional 6,325 shares during the last quarter.

Analyst Upgrades and Downgrades

PHVS has been the topic of several research reports. UBS Group set a $74.00 price target on Pharvaris in a research note on Wednesday, May 13th. Wall Street Zen raised Pharvaris from a “strong sell” rating to a “sell” rating in a research note on Saturday. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Pharvaris in a research report on Tuesday, March 3rd. Citigroup reissued a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $49.18.

Trending Headlines about Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates for Pharvaris across multiple quarters and fiscal years, including higher forecasts for FY2026 through FY2030, and maintained a Buy rating with a $60 price target.
• Neutral Sentiment: Pharvaris recently reported a smaller-than-expected quarterly loss, with EPS of ($0.70) versus the consensus estimate of ($0.82), which may support sentiment but does not change the company’s near-term loss profile.
• Negative Sentiment: Insider selling by Director Robert Glassman and insider Wim Souverijns, both of whom sold 10,000 shares, may temper enthusiasm slightly because it can be viewed as reduced insider confidence. SEC filing for Robert Glassman sale SEC filing for Wim Souverijns sale

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.